Cardinal Health 414 patent expiration

1. Lymphoseek Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6409990 CARDINAL HEALTH 414 Macromolecular carrier for drug and diagnostic agent delivery
May, 2025

(7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9439985 CARDINAL HEALTH 414 Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran
Jan, 2029

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-687) Jun 13, 2017
New Chemical Entity Exclusivity(NCE) Mar 13, 2018
Orphan Drug Exclusivity(ODE) Jun 13, 2021
Orphan Drug Exclusivity(ODE-67) Jun 13, 2021
New Patient Population(NPP) May 19, 2024

Drugs and Companies using TECHNETIUM TC-99M TILMANOCEPT ingredient

NCE-1 date: 13 March, 2017

Market Authorisation Date: 13 March, 2013

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

LYMPHOSEEK KIT family patents

Family Patents